Document is current
Any future updates will be listed below
-
Authors
Clegg, Lindsay E. https://orcid.org/0000-0001-8558-9341
Penland, Robert C.
Bachina, Srinivas
Boulton, David W.
Thuresson, Marcus
Heerspink, Hiddo J. L.
Gustavson, Stephanie
Sjöström, C. David
Ruggles, James A.
Hernandez, Adrian F.
Buse, John B.
Mentz, Robert J.
Holman, Rury R.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01144338 at ClinicalTrials.govDocuments that mention this clinical trial
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol
https://doi.org/10.1136/bmjopen-2014-005942
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
https://doi.org/10.2337/ds16-0026
Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.2337/dc18-2028
Contemporary and Novel Therapeutic Options for Hypertriglyceridemia
https://doi.org/10.1016/j.clinthera.2015.08.001
Hispanic representation in diabetes cardiovascular outcomes trials
https://doi.org/10.1136/bmjdrc-2019-000656
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
https://doi.org/10.1016/j.ahj.2015.02.002
Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
https://doi.org/10.1016/j.clinthera.2014.11.008
Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) (Results)
https://doi.org/10.2337/dc19-0950
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
https://doi.org/10.2337/dc15-2237
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
https://doi.org/10.1186/s12933-019-0942-x
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
https://doi.org/10.1016/j.ahj.2015.12.009
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
https://doi.org/10.2337/dc18-1871
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
https://doi.org/10.1016/s0140-6736(12)61267-7
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
https://doi.org/10.1016/s0140-6736(13)62154-6
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
https://doi.org/10.2337/dc19-1065
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
https://doi.org/10.1186/s12933-022-01555-z
Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL (Results)
https://doi.org/10.2337/dc19-1079
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 15 August 2019
Accepted: 5 October 2019
First Online: 22 October 2019
Ethics approval and consent to participate
: The protocol was approved by local ethics committees and institutional review boards at each participating center. All subjects provided written informed consent.
: Not applicable.
: LEC, RCP, SB, DWB, SG, CDS, and JR are employees and/or shareholders of AstraZeneca. SG’s spouse is also an employee of AstraZeneca. HJLH serves on advisory panels for Boehringer Ingelheim GmbH and Merck & Co., Inc, and is a consultant for AbbVie Inc., AstraZeneca, Fresenius SE & Co. KGaA, Janssen Research & Development, and Mitsubishi Tanabe Pharma Corporation. RCP is a stockholder of Novartis Pharmaceuticals Corporation. DWB is a stockholder of Bristol-Myers Squibb Company. MT is a consultant for AstraZeneca. RJM has received research support and honoraria from AstraZeneca, GlaxoSmithKline plc., and Merck & Co., Inc. AFH is a consultant for Bayer AG & Boehringer Ingelheim Pharmaceuticals, Inc., and receives research support from AstraZeneca, GlaxoSmithKline plc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., and Novartis Pharmaceuticals Corporation. RRH has attended advisory boards at Elcelyx Therapeutics, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Amylin, and Eli Lilly. RRH has given lectures supported by Bayer AG, Eli Lilly, Merck & Co., Inc, and Novo Nordisk A/S, and received research support and honoraria from AstraZeneca, Bayer AG, and Merck & Co., Inc. RRH is an Emeritus NIHR Senior Investigator. JBB’s contracted consulting fees are paid to the University of North Carolina by Adocia, AstraZeneca, Dance Biopharm, Eli Lilly, MannKind, NovaTarg, Novo Nordisk, Senseonics, vTv Therapeutics, and Zafgen; grant support from Novo Nordisk, Sanofi, and vTv Therapeutics. He is a consultant to Cirius Therapeutics Inc, CSL Behring, Neurimmune AG, and Whole Biome Inc. He holds stock options in Mellitus Health, PhaseBio, Stability Health, and Whole Biome Inc. He is supported by a grant from the National Institutes of Health (UL1TR002489).
